1V209(Synonyms: TLR7 agonist T7)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

1V209 (Synonyms: TLR7 agonist T7) 纯度: 99.52%

1V209 (TLR7 agonist T7) 是 Toll-like receptor 7 (TLR7) 激动剂,具有抗肿瘤作用。1V209 可与各种多糖缀合,以改善其水溶性,增强功效并保持低毒性。

1V209(Synonyms: TLR7 agonist T7)

1V209 Chemical Structure

CAS No. : 1062444-54-5

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥1383 In-stock
1 mg ¥580 In-stock
5 mg ¥1750 In-stock
10 mg ¥3000 In-stock
25 mg ¥6000 In-stock
50 mg ¥9000 In-stock
100 mg ¥13500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

1V209 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • Anti-Cancer Compound Library
  • Small Molecule Immuno-Oncology Compound Library
  • Antioxidants Compound Library
  • Reprogramming Compound Library
  • Oxygen Sensing Compound Library
  • Pyroptosis Compound Library
  • Anti-Breast Cancer Compound Library

生物活性

1V209 (TLR7 agonist T7) is a Toll-like receptor 7 (TLR7) agonist and has anti-tumor effects. 1V209 can be conjugated with various polysaccharides to improve its water solubility, and enhance its efficacy, and maintain low toxicity[1][2].

IC50 & Target[1]

TLR7

 

体外研究
(In Vitro)

1V209 (0.1-10 μM) treatment significantly stimulates TNFα production in RAW246.7 cells[1].
1V209 (18 hours) treatment increases IL-6 production comparain bone marrow derived dendritic cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

The intravenous (IV) administration of the formulation to mice bearing 4T1 breast cancer tumors results in nanoparticle accumulation in tumors, reduction in primary tumor growth, and inhibition of lung metastases, as compared to saline-treated animals. Mice administered 1V209 experience significantly increases plasma levels of proinflammatory cytokines IL-6, IP-10, and MCP-1 at 2 h following IV administration[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

359.34

Formula

C16H17N5O5

CAS 号

1062444-54-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 83.33 mg/mL (231.90 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.7829 mL 13.9144 mL 27.8288 mL
5 mM 0.5566 mL 2.7829 mL 5.5658 mL
10 mM 0.2783 mL 1.3914 mL 2.7829 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (5.79 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.79 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (5.79 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.79 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Battistella C, et al. Delivery of Immunotherapeutic Nanoparticles to Tumors via Enzyme-Directed Assembly. Adv Healthc Mater. 2019 Dec;8(23):e1901105.

    [2]. Shinchi H, et al. Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides. Bioconjug Chem. 2015 Aug 19;26(8):1713-23.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务